The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

Nearly one in four European pharmaceutical companies remains vulnerable to regulatory risks due to inadequate quality systems ...

Rapid three-week deployment, onsite support from two-time Nobel Laureate, and deep Canada-Korea collaboration underscore ...

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

Nova Pneuma Inc. ("NPI"), the Delaware incorporated and wholly owned subsidiary of Lee's Pharmaceutical Holdings Limited ...

The discovery, featured on the cover of Analytical Chemistry, could potentially slow the progression to full-blown diabetes.

First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, Awarded for AI Roleplay and Field Simulation Excellence ...

The Emirates Drug Establishment (EDE), in collaboration with the Drug Information Association (DIA), Middle East and Africa Office, organised the first Clinical Research Forum in the UAE at the ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...

The U.K. company presented findings that its 360 e-Lung technology could potentially speed up the diagnosis of progressive pulmonary fibrosis by nearly two years in more than half of the patients ...

Brown Advisory, an investment management company, released its “Brown Advisory Large-Cap Growth Strategy” third-quarter 2025 ...

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...